Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

NCT02626338 is registered in ClinicalTrials.gov with Arog Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02626338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02626338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Pilot Study of Crenolanib Combined With Standard Salvage Chmetherapy in Subjects With Relapsed/Refractory Acute Myeloid Leukemia
Lead sponsor
Arog Pharmaceuticals, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
February 29, 2016
Completion date
February 28, 2018
Enrollment
16 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory acute myeloid leukemia (aml)